OMER News and Press, Omeros Corporation From 08/17/22

Omeros ( NASDAQ: OMER ) said on Wednesday that the United States Food and Drug Administration had given an interim response to the its formal dispute resolution request that it had submitted in June, appealing the decision by the agency review division to issue a comp...

Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company’s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by the FDA review division t...

Omeros has had it rough over the last two years after the FDA delayed narsoplimab’s PDUFA and eventually sent a CRL. OMER plummeted from around $20 per share to $2. The market sell-off put OMER under additional selling pressure and moved the ticker into the oversold territory. ...

Omeros Corporation. (OMER) Q2 2022 Earnings Conference Call August 09, 2022, 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Gregory Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melf...

Omeros press release ( NASDAQ: OMER ): Q2 GAAP EPS of -$0.49. At June 30, 2022, Omeros had $122.6 million of cash, cash equivalents and short-term investments available for operations, which is a reduction of $19.7 million from March 31, 2022. For further details see...

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indicatio...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2022, on Tuesday, August 9, 2022, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p....

Shares of the small-cap biopharma Omeros Corporation (NASDAQ: OMER) were up by a healthy 11.4%, on moderate volume, as of 1:48 p.m. ET Friday afternoon. The biotech's double-digit move higher is particularly noteworthy in light of the fact that the industry as a whole is losing ...

Gainers: Ayala Pharmaceuticals ( AYLA ) +27% . GeoVax Labs ( GOVX ) +20% . Senti Biosciences ( SNTI ) +17% . Omeros ( OMER ) +15% . CVRx ( CVRX ) +9% . Losers: Nutriband ( NTRB ) -15% . Bausch Health Companies ...